CSCI (Cosciens Biopharma) Debt-to-Asset : 0.04 (As of Sep. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Cosciens Biopharma Debt-to-Asset?

Cosciens Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.41 Mil. Cosciens Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.21 Mil. Cosciens Biopharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $43.77 Mil. Cosciens Biopharma's debt to asset for the quarter that ended in Sep. 2024 was 0.04.

Cosciens Biopharma Debt-to-Asset Historical Data

The historical data trend for Cosciens Biopharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosciens Biopharma Debt-to-Asset Chart

Cosciens Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.12

0.10

0.09

0.07

Cosciens Biopharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.07	0.07	0.07	0.03	0.04

Competitive Comparison of Cosciens Biopharma's Debt-to-Asset

For the Biotechnology subindustry, Cosciens Biopharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cosciens Biopharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Cosciens Biopharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cosciens Biopharma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.299	+	1.396)	/	23.704
	=	0.07

Cosciens Biopharma's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.405	+	1.211)	/	43.769
	=	0.04

Cosciens Biopharma (NAS:CSCI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Cosciens Biopharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosciens Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (NAS:CSCI) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

ET8:Germany CSCI:Canada

Address

c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.